Corcept Therapeutics. Every tracked FinTwit mention of $CORT, newest first. 6 mentions since the first on Feb 5, 2026. See the price chart.
March 2026 · 3 mentions
Mar 26
Adam Feuerstein ✡️ — @JacobPlieth The $CORT Lifyorli label is a safety and drug-interaction horror show.↗
Mar 26
Jacob Plieth — Here's prescribing info for $CORT Lifyorli -> https://t.co/i46Whl5lX6 Why so different from the experience in Cushing's? https://t.co/EqvbCApqHn↗
Mar 25
Adam Feuerstein ✡️ — FDA approved $CORT relacorilant for advanced ovarian cancer.
I was wrong on this one. I thought the drug's liver injury risk and the higher rate of side effects would tip the sca…↗
February 2026 · 3 mentions
Feb 19
Adam Feuerstein ✡️ — @Sanctuary_Bio You mean the PROC application with a drug that carries a DILI risk and showed minimal benefit? Good luck, $CORT!↗
Feb 5
Adam Feuerstein ✡️ — Dispute between Corcept Therapeutics $CORT, FDA runs deep. Concerns over a potential risk of liver injury induced by the company’s drug raises doubts.
https://t.co/VwzSEzdZwa↗
Feb 5
Adam Feuerstein ✡️ — In this week's Biotech Scorecard newsletter:
-- A preview of the $NKTR rezpeg maintenance data in atopic dermatitis. I also chatted with CEO Howard Robin during JPM Week.
-- A d…↗